| Literature DB >> 33441554 |
Matthias Gromeier1,2, Michael C Brown1,2, Gao Zhang1,2, Xiang Lin3, Yeqing Chen3, Zhi Wei3, Nike Beaubier4, Hai Yan2,5, Yiping He2,5, Annick Desjardins1,2, James E Herndon2,6, Frederick S Varn7, Roel G Verhaak7, Junfei Zhao8, Dani P Bolognesi9,10, Allan H Friedman1,2, Henry S Friedman1,2, Frances McSherry6, Andrea M Muscat11, Eric S Lipp1,2, Smita K Nair9, Mustafa Khasraw1,2, Katherine B Peters1,2, Dina Randazzo1,2, John H Sampson1,2, Roger E McLendon2,5, Darell D Bigner1,2, David M Ashley12,13.
Abstract
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tumor mutation burden is associated with longer survival after recombinant polio virotherapy or after immune checkpoint blockade in recurrent glioblastoma patients. A relationship between tumor mutation burden and survival is not observed in cohorts of immunotherapy naïve newly diagnosed or recurrent glioblastoma patients. Transcriptomic analyses reveal an inverse relationship between tumor mutation burden and enrichment of inflammatory gene signatures in cohorts of recurrent, but not newly diagnosed glioblastoma tumors, implying that a relationship between tumor mutation burden and tumor-intrinsic inflammation evolves upon recurrence.Entities:
Year: 2021 PMID： 33441554 DOI： 10.1038/s41467-020-20469-6
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919